Pressmeddelanden från ALK-Abello

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco

ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco

GlobeNewswire • 08 Jan 17:17

ALK – Financial calendar for the 2026 financial year

ALK – Financial calendar for the 2026 financial year

GlobeNewswire • 22 Dec 2025 16:13

Major shareholder announcement

Major shareholder announcement

GlobeNewswire • 19 Dec 2025 22:47

ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America

ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America

GlobeNewswire • 01 Dec 2025 15:35

Nine-month interim report (Q3) 2025 (unaudited)

Nine-month interim report (Q3) 2025 (unaudited)

GlobeNewswire • 12 Nov 2025 17:22

ALK upgrades its full-year outlook

ALK upgrades its full-year outlook

GlobeNewswire • 12 Nov 2025 17:16

Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025

Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025

GlobeNewswire • 06 Nov 2025 17:02

ALK and GenSci partner to expand the AIT market in China

ALK and GenSci partner to expand the AIT market in China

GlobeNewswire • 17 Sep 2025 09:44

Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray

Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray

GlobeNewswire • 08 Sep 2025 14:22

ALK expands the Executive Leadership Team to include key commercial regions

ALK expands the Executive Leadership Team to include key commercial regions

GlobeNewswire • 04 Sep 2025 12:31

Six-month interim report (Q2) 2025 (unaudited)

Six-month interim report (Q2) 2025 (unaudited)

GlobeNewswire • 21 Aug 2025 07:30

Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025

Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025

GlobeNewswire • 14 Aug 2025 14:57

ALK upgrades its full-year revenue outlook

ALK upgrades its full-year revenue outlook

GlobeNewswire • 12 Aug 2025 14:45

ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system

ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system

GlobeNewswire • 21 Jul 2025 12:25

EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK

EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK

GlobeNewswire • 18 Jul 2025 14:01

First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany

First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany

GlobeNewswire • 26 Jun 2025 09:17

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025

GlobeNewswire • 16 Jun 2025 14:03

ALK participates at Jefferies Global Healthcare Conference 2025 in New York

ALK participates at Jefferies Global Healthcare Conference 2025 in New York

GlobeNewswire • 04 Jun 2025 16:48

ITULATEK® approved for treatment of children and adolescents in Canada

ITULATEK® approved for treatment of children and adolescents in Canada

GlobeNewswire • 08 May 2025 16:28

Three-month interim report (Q1) 2025 (unaudited)

Three-month interim report (Q1) 2025 (unaudited)

GlobeNewswire • 06 May 2025 07:30

ALK enters into neffy® co-promotion agreement in the USA

ALK enters into neffy® co-promotion agreement in the USA

GlobeNewswire • 02 May 2025 13:59

Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025

Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025

GlobeNewswire • 29 Apr 2025 16:39

ITULAZAX® tree pollen tablet approved for treatment of children in Europe

ITULAZAX® tree pollen tablet approved for treatment of children in Europe

GlobeNewswire • 23 Apr 2025 15:58

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

GlobeNewswire • 03 Apr 2025 16:24

Annual General Meeting in ALK-Abelló A/S held on 13 March 2025

Annual General Meeting in ALK-Abelló A/S held on 13 March 2025

GlobeNewswire • 13 Mar 2025 18:06

ACARIZAX® approved in Canada for treatment of young children

ACARIZAX® approved in Canada for treatment of young children

GlobeNewswire • 07 Mar 2025 14:34

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

GlobeNewswire • 04 Mar 2025 22:20

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

GlobeNewswire • 27 Feb 2025 21:51

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

GlobeNewswire • 21 Feb 2025 15:59

Annual General Meeting in ALK-Abelló A/S on 13 March 2025

Annual General Meeting in ALK-Abelló A/S on 13 March 2025

GlobeNewswire • 19 Feb 2025 14:46

Annual report 2024: ALK delivers 15% sales growth with profits up 65%

Annual report 2024: ALK delivers 15% sales growth with profits up 65%

GlobeNewswire • 19 Feb 2025 07:32

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

GlobeNewswire • 12 Feb 2025 17:02

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

GlobeNewswire • 30 Jan 2025 10:13

ALK – Financial calendar for the 2025 financial year

ALK – Financial calendar for the 2025 financial year

GlobeNewswire • 20 Dec 2024 17:09

Positive results advance peanut tablet to phase II development

Positive results advance peanut tablet to phase II development

GlobeNewswire • 18 Dec 2024 12:51

ACARIZAX® approved in Europe for treatment of young children

ACARIZAX® approved in Europe for treatment of young children

GlobeNewswire • 12 Dec 2024 16:06

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

GlobeNewswire • 27 Nov 2024 13:45

Nine-month interim report (Q3) 2024 (unaudited)

Nine-month interim report (Q3) 2024 (unaudited)

GlobeNewswire • 14 Nov 2024 07:30

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

GlobeNewswire • 09 Nov 2024 23:30

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

GlobeNewswire • 07 Nov 2024 12:09

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

GlobeNewswire • 27 Aug 2024 17:30

Six-month interim report (Q2) 2024

Six-month interim report (Q2) 2024

GlobeNewswire • 22 Aug 2024 17:49

ALK upgrades its full-year revenue and earnings outlook

ALK upgrades its full-year revenue and earnings outlook

GlobeNewswire • 22 Aug 2024 17:38

Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024

Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024

GlobeNewswire • 14 Aug 2024 11:58

ALK upgrades its full-year revenue and earnings outlook

ALK upgrades its full-year revenue and earnings outlook

GlobeNewswire • 21 Jun 2024 18:43

ALK provides update on regulatory process for the house dust mite allergy tablet in China

ALK provides update on regulatory process for the house dust mite allergy tablet in China

GlobeNewswire • 21 Jun 2024 18:38

ALK launches new growth strategy and 2028 financial ambitions

ALK launches new growth strategy and 2028 financial ambitions

GlobeNewswire • 03 Jun 2024 18:02

ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies

ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies

GlobeNewswire • 03 Jun 2024 07:00

ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review

ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review

GlobeNewswire • 30 May 2024 13:44

Listen in on ALK’s Capital Markets Day on 4 June 2024

Listen in on ALK’s Capital Markets Day on 4 June 2024

GlobeNewswire • 29 May 2024 10:56

Three-month interim report (Q1) 2024 (unaudited)

Three-month interim report (Q1) 2024 (unaudited)

GlobeNewswire • 02 May 2024 19:43

ALK upgrades its full-year revenue outlook

ALK upgrades its full-year revenue outlook

GlobeNewswire • 02 May 2024 19:26

Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024

Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024

GlobeNewswire • 24 Apr 2024 16:35

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

GlobeNewswire • 03 Apr 2024 15:40

Save the date for ALK’s Capital Markets Day on 4 June 2024

Save the date for ALK’s Capital Markets Day on 4 June 2024

GlobeNewswire • 26 Mar 2024 14:00

Annual General Meeting in ALK-Abelló A/S held on 14 March 2024

Annual General Meeting in ALK-Abelló A/S held on 14 March 2024

GlobeNewswire • 14 Mar 2024 17:40

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

GlobeNewswire • 05 Mar 2024 16:45

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

GlobeNewswire • 04 Mar 2024 16:00

Annual General Meeting in ALK-Abelló A/S on 14 March 2024

Annual General Meeting in ALK-Abelló A/S on 14 March 2024

GlobeNewswire • 16 Feb 2024 14:00

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

GlobeNewswire • 12 Feb 2024 16:15

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

GlobeNewswire • 12 Feb 2024 11:30

Annual report 2023: ALK delivers 9% sales growth with profits up 50%

Annual report 2023: ALK delivers 9% sales growth with profits up 50%

GlobeNewswire • 08 Feb 2024 13:35

ALK and McMaster researchers discover new cell that remembers allergies

ALK and McMaster researchers discover new cell that remembers allergies

GlobeNewswire • 07 Feb 2024 20:10

ALK’s 2030 CO2 reduction targets have been approved by SBTi

ALK’s 2030 CO2 reduction targets have been approved by SBTi

GlobeNewswire • 05 Feb 2024 09:30

Release date of annual report 2023 for ALK and webcast

Release date of annual report 2023 for ALK and webcast

GlobeNewswire • 31 Jan 2024 09:44

ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review

ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review

GlobeNewswire • 25 Jan 2024 13:15

ALK completes first part of phase 1 trial with peanut SLIT-tablet

ALK completes first part of phase 1 trial with peanut SLIT-tablet

GlobeNewswire • 18 Jan 2024 15:34

ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy

ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy

GlobeNewswire • 04 Jan 2024 14:00

ALK – Financial calendar for the 2024 financial year

ALK – Financial calendar for the 2024 financial year

GlobeNewswire • 20 Dec 2023 10:45

ALK expands partnership with Torii in Japan

ALK expands partnership with Torii in Japan

GlobeNewswire • 12 Dec 2023 16:08

Nine-month interim report (Q3) 2023

Nine-month interim report (Q3) 2023

GlobeNewswire • 15 Nov 2023 07:30

Release date of nine-month interim report (Q3) 2023 for ALK and audio cast

Release date of nine-month interim report (Q3) 2023 for ALK and audio cast

GlobeNewswire • 09 Nov 2023 13:46

Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children

Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children

GlobeNewswire • 11 Oct 2023 16:13

Six-month interim report (Q2) 2023

Six-month interim report (Q2) 2023

GlobeNewswire • 24 Aug 2023 07:30

Release date of six-month interim report (Q2) 2023 for ALK and audio cast

Release date of six-month interim report (Q2) 2023 for ALK and audio cast

GlobeNewswire • 18 Aug 2023 12:45

President & CEO Carsten Hellmann to step down end 2023. Peter Halling appointed as his successor

President & CEO Carsten Hellmann to step down end 2023.

GlobeNewswire • 19 Jun 2023 08:40

Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s house dust mite tablet in young children

Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s house dust mite tablet in young children

GlobeNewswire • 08 Jun 2023 16:27

Three-month interim report (Q1) 2023

Three-month interim report (Q1) 2023

GlobeNewswire • 09 May 2023 07:20

Release date of three-month interim report (Q1) 2023 for ALK and audio cast

Release date of three-month interim report (Q1) 2023 for ALK and audio cast

GlobeNewswire • 01 May 2023 10:18

ALK announces preliminary Q1 figures and confirms its full-year revenue and earnings outlook

ALK announces preliminary Q1 figures and confirms its full-year revenue and earnings outlook

GlobeNewswire • 17 Apr 2023 18:15

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

GlobeNewswire • 31 Mar 2023 17:30

Annual General Meeting in ALK-Abelló A/S held on 23 March 2023

Annual General Meeting in ALK-Abelló A/S held on 23 March 2023

GlobeNewswire • 23 Mar 2023 17:17

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

GlobeNewswire • 02 Mar 2023 17:14

Annual General Meeting in ALK on 23 March 2023

Annual General Meeting in ALK on 23 March 2023

GlobeNewswire • 27 Feb 2023 10:00

ALK appoints Claus Steensen Sølje as new Chief Financial Officer (CFO)

ALK appoints Claus Steensen Sølje as new Chief Financial Officer (CFO)

GlobeNewswire • 10 Feb 2023 08:30

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

GlobeNewswire • 08 Feb 2023 17:04

Regulatory filing for house dust mite allergy tablet accepted for review in China

Regulatory filing for house dust mite allergy tablet accepted for review in China

GlobeNewswire • 03 Feb 2023 12:48

Annual report 2022: ALK delivers sales growth of 13% with profits up 33% in 2022

Annual report 2022: ALK delivers sales growth of 13% with profits up 33% in 2022

GlobeNewswire • 03 Feb 2023 12:08

Release date of annual report 2022 for ALK and audio cast

Release date of annual report 2022 for ALK and audio cast

GlobeNewswire • 27 Jan 2023 14:12

Henriette Mersebach to succeed Henrik Jacobi as Executive Vice President, R&D at ALK

Henriette Mersebach to succeed Henrik Jacobi as Executive Vice President, R&D at ALK

GlobeNewswire • 21 Dec 2022 08:34

ALK – Financial calendar for the 2023 financial year

ALK – Financial calendar for the 2023 financial year

GlobeNewswire • 19 Dec 2022 17:33

Management change at ALK

Management change at ALK

GlobeNewswire • 30 Nov 2022 17:24

Nine-month interim report (Q3) 2022

Nine-month interim report (Q3) 2022

GlobeNewswire • 10 Nov 2022 07:30

Release date of nine-month interim report (Q3) 2022 for ALK and audio cast

Release date of nine-month interim report (Q3) 2022 for ALK and audio cast

GlobeNewswire • 03 Nov 2022 14:15

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

GlobeNewswire • 25 Aug 2022 17:13

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

GlobeNewswire • 16 Aug 2022 16:49

Six-month interim report (Q2) 2022

Six-month interim report (Q2) 2022

GlobeNewswire • 11 Aug 2022 07:29

Release date of six-month interim report (Q2) 2022 for ALK and audio cast

Release date of six-month interim report (Q2) 2022 for ALK and audio cast

GlobeNewswire • 04 Aug 2022 15:32

ALK upgrades its full-year financial outlook

ALK upgrades its full-year financial outlook

GlobeNewswire • 04 Aug 2022 13:37

ALK spotlights the impact of respiratory allergies on children at EAACI Congress

ALK spotlights the impact of respiratory allergies on children at EAACI Congress

GlobeNewswire • 03 Jul 2022 12:45